

Appl. No. : Unkn  
Filed : Herewith

*A2 Sub E47* 6. (Amended) A method according to **[any one of]** claim[s] 1 **[to 5]** wherein the viral infection is a hepatitis infection or other viral infection of the human or animal liver.

7. (Amended) A method according to **[any one of]** claim[s] 2 **[to 6]** wherein said cell is a liver cell.

8. (Amended) A substance identified by the method of **[any one of the preceeding claims]** claim 1.

*A3 CONT'D* 13. (Amended) **[A] An isolated** polynucleotide encoding a protein according to claim 11 **[or 12 sequence for use in affecting a viral infection]**.

14. (Amended) A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of] a protein according to claim 11 [or 12, or a polynucleotide according to claim 13 in the manufacture of a medicament for use in affecting a viral infection], and a pharmaceutically acceptable non-toxic vehicle.

15. (Amended) A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of a substance in the manufacture of a medicament for use in affecting a viral infection, wherein the] a substance [has been] identified by the method of [any one of] claim[s] 1 [to 7], and a pharmaceutically acceptable non-toxic vehicle.

16. (Amended) A pharmaceutical composition for treating viral infections in a mammal, comprising [Use of a substance in the manufacture of a medicament for the use in affecting a viral infection wherein said] a substance which can upregulate expression of ADRP in a mammalian cell, and a pharmaceutically acceptable non-toxic vehicle.

*00001010100000*  
Please delete Claim 9.

Please add the following claims:

*Sub E57* 17. A method according to claim-5 wherein the viral infection is a hepatitis infection or other viral infection of the human or animal liver.

18. A method according to claim-5 wherein said cell is a liver cell.

*A4 CONT'D* ~~19. A substance identified by the method of claim 5.~~

20. A pharmaceutical composition for treating viral infections in a mammal, comprising a polynucleotide according to claim 13 in the manufacture of a medicament for use in affecting a viral infection, and a pharmaceutically acceptable non-toxic vehicle.